Research Article

Interleukin-22 Might Act as a Double-Edged Sword in Type 2 Diabetes and Coronary Artery Disease

Fangchen Gong, Jin Wu, Ping Zhou, Mengyao Zhang, Jingning Liu, Ying Liu, Xiang Lu, and Zhengxia Liu

1Department of Geriatrics, The Second Affiliated Hospital, Nanjing Medical University, Jiangsu 210029, China
2Department of Neurology, The Second Affiliated Hospital, Nanjing Medical University, Jiangsu 210029, China

Correspondence should be addressed to Xiang Lu; luxiang66@njmu.edu.cn and Zhengxia Liu; liuzzx0503@163.com

Received 13 April 2016; Accepted 19 July 2016

Academic Editor: Chiara De Luca

Copyright © 2016 Fangchen Gong et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Type 2 diabetes mellitus (T2DM) and coronary artery disease (CAD) are both characterized by chronic low-grade inflammation. The role of Th17 and its related cytokines in T2DM and CAD is unclear. Here we investigated the serum levels of five Th17-related cytokines (IL-17, IL-22, MIP-3α, IL-9, and IL-27) in T2DM, CAD, and T2DM-CAD comorbidity patients. IL-22 was found to be elevated in all three conditions. Elevated serum IL-22 was independently associated with the incidence of T2DM and CAD. Conversely, IL-22 was found to protect endothelial cells from glucose- and lysophosphatidylcholine- (LPC-) induced injury, and IL-22R1 expression on endothelial cells was increased upon treatment with high glucose and LPC. Blocking of IL-22R1 with IL-22R1 antibody diminished the protective role of IL-22. Our results suggest that IL-22 functions as a double-edged sword in T2DM and CAD and that IL-22 may be used in the treatment of chronic inflammatory diseases such as T2DM and CAD.

1. Introduction

Type 2 diabetes mellitus (T2DM) and coronary artery disease (CAD) are leading causes of morbidity worldwide. T2DM and CAD are metabolic diseases and share common risk factors such as obesity, hypertension, and dyslipidemia [1]. In addition to the traditional risk factors, chronic low-grade inflammation has now emerged as a major trigger for both these conditions [2]. Accumulating evidences have revealed that multiple types of immune cells are involved in T2DM and CAD pathogenesis [3]. In recent years, the involvement of adaptive immunity in T2DM and CAD has received considerable attention. Activated adaptive immune competent cells are present in atherosclerotic lesions [4, 5]. The presence of activated CD4+ T cells in adipose tissue also suggests immune participation in T2DM [6].

As a newly characterized CD4+ T-cell subtype, Th17 cells have also been shown to be involved in the pathogenesis of atherosclerosis and T2DM. Th17 cells have been observed to accumulate in murine and human atherosclerotic lesions and have also been suggestive of contributing to inflammation and hyperglycemia in T2DM patients [7–9]. Th17 cells produce a series of cytokines such as IL-17 and IL-22 and are regulated by various cytokines. IL-17, a signature cytokine of Th17, has been reported to be associated with stable plaque phenotype and plaque instability in different trials [10, 11]. IL-22, another cytokine secreted by Th17, has been identified to alleviate metabolic disorders in one study. Conversely, in other studies, IL-22 was found to aggravate T2DM condition [12, 13]. MIP-3α (also known as CCL20), a ligand for CCR6, plays an important role in the migration of Th17 cells to inflamed sites [14]. IL-9 induces Th17 cells to differentiate and enhances IL-17A production by cultured human peripheral blood mononuclear cells or CD4+ T cells [15]. IL-27 induces p-STAT3 to promote Th17 differentiation in the absence of STAT1 [16]. These Th17 regulators also exert their roles in T2DM and CAD, although relevant clinical studies are few [14, 17–19].

In the current study, we evaluated the serum levels of Th17-related cytokines (IL-17, IL-22, MIP-3α, IL-9, and IL-27) during immunogenesis. Among these cytokines, IL-22 was found to be elevated in CAD, T2DM, and T2DM-CAD
2. Materials and Methods

2.1. Study Population. The study was approved by the Institutional Review Board of Nanjing Medical University. Written consent was obtained from each patient. Five-hundred and fifteen patients were recruited from the Second Affiliated Hospital of Nanjing Medical University from 2012 to 2015. Initially, we included 78 people to comprehensively analyze five Th17-related cytokines (Batch 1). Then, 437 people were divided into four groups in each batch: (1) normal healthy volunteers (Batch 1, n = 15; Batch 2, n = 110); (2) patients with T2DM (Batch 1, n = 18; Batch 2, n = 58); (3) patients with CAD (Batch 1, n = 24; Batch 2, n = 132); (4) patients with CAD and T2DM comorbidity (Batch 1, n = 21; Batch 2, n = 137).

The CAD-group patients were diagnosed on the basis of the results of coronary angiography, and patients with at least one coronary stenosis of >50% of the luminal diameter were included. Furthermore, the stable angina (SA) subgroup included patients with typical effort angina that was accompanied by a downward or horizontal ST-segment depression of >1 mm during an exercise test; the unstable angina (UA) subgroup included patients who exhibited chest pain at rest, with definite ST-segment changes and/or T-wave inversions; the acute myocardial infarction (AMI) subgroup included patients who exhibited significantly elevated levels of creatine kinase MB and cardiac troponin I as well as a typical clinical electrocardiogram manifestation. The CAD group included patients who had normal fasting glucose levels and no history of glucose-lowering medical treatment. The diagnosis of T2DM was based on the results of oral glucose tolerance test (OGTT) and medical treatment history; their coronary angiograms were normal. The control group was recruited according to the following criteria: no history of diabetes, normal glucose tolerance in OGTT, and normal coronary angiograms.

Patients with peripheral vascular disease, thrombotic stroke, nephropathy, retinopathy, inflammatory diseases of any cause, other systemic and metabolic diseases, asthma, malignancy, liver diseases, kidney diseases, and pregnant women were excluded from the study.

2.2. Cytokine Quantitative Assays. Serum was obtained by centrifugation and stored at −80°C for the determination of cytokine levels. Protein expression (IL-17, IL-22, MIP-3α, IL-9, and IL-27) was measured using a magnetic bead kit based on the Luminex® technology. Briefly, capture antibodies (Millipore) were conjugated to Luminex beads. Detection antibodies (Millipore) were conjugated to biotin through the custom service provided by Millipore. Serum was diluted with an equal volume of MILLIPLEX® MAP cell assay buffer (Millipore). Capture antibody beads were diluted in 25 μL of MILLIPLEX MAP cell assay buffer and added to a magnetic plate (Millipore). Then, 25 μL of the diluted serum was transferred to each well of the solid plate and incubated for 2 h at room temperature with shaking. After incubation, the beads were washed twice with wash buffer, and 25 μL of detection antibodies was added into each well and incubated for 1 h at room temperature with shaking. Then, 25 μL of MILLIPLEX MAP streptavidin-phycocerythrin (Millipore) was added and incubated for 30 min at room temperature with shaking. Finally, sheath fluid was added after washing, and the signal was read using Luminex FLEXMAP 3D™.

2.3. Serum IL-22 Enzyme-Linked Immunosorbent Assay (ELISA). Peripheral blood was collected into tubes containing heparin-anticoagulant. Serum was obtained by centrifugation and stored at −80°C for the determination of cytokine levels. Serum IL-22 levels were determined with a quantitative sandwich enzyme immunoassay technique in accordance with the manufacturer’s recommendations (Joyee Biotechnics, China).

2.4. Cell Culture. Human umbilical vein endothelial cells (HUVECs) were obtained from the American Type Culture Collection (Manassas, VA, USA). HUVECs were cultured in endothelial cell medium (ECM) supplemented with 5% fetal bovine serum, 100 U/mL penicillin, and 0.1 mg/mL streptomycin (all from ScienCell, USA) and incubated at 37°C in 5% CO₂/95% air environment. When the cells reached 70%–80% confluence, new medium was added before drug treatment.

2.5. Cellular Stimuli with a High Concentration of Glucose, LPC, or a Combination of the Two. The original serum and glucose-containing media were removed from the dishes, and the cells were washed three times with phosphate-buffered saline. Various concentrations of glucose (5, 15, 30, 60, and 90 mM) (Sigma, USA) or LPC (5, 10, 20, and 40 μg/mL) (Sigma, USA) were then added to the culture medium for the indicated times (24 or 48 h). To investigate the effects of the combined stimuli, cells were incubated with glucose (30 mM) and LPC (10 μg/mL) for 48 h.

2.6. Cell Viability Assays. Cell viability was assessed using CCK-8 according to the manufacturer’s recommendations (Kaiji, China). CCK-8 solution (10 μL) was added to each well, and the cultures were incubated at 37°C for 1 h. The results were expressed as the percentage of viable cells relative to the control group after measuring the absorbance at 450 nm. Each experiment included six readings for each experimental condition, and the experiments were repeated thrice.

2.7. Apoptosis Assay. Cells were trypsinized with ethylene diamine tetraacetic acid-free trypsin and then washed in serum-containing media. Cells (1 × 10⁶) were collected by centrifugation, resuspended in 100 μL of 1x binding buffer
containing 5 μL of Annexin V-FITC and 5 μL of propidium iodide (BD Biosciences, US), and incubated at room temperature in the dark for 15 min. Apoptosis data were acquired on FACSCanto™ II system (BD Bioscience, US) and were analyzed using the FlowJo software. The results were obtained from three independent experiments.

2.8. IL-22R1 Expression Assay. To analyze the expression of IL-22R1, HUVECs were stained with anti-human IL-22R1 antibody (AF2770; R&D systems, US). Nonspecific staining was evaluated using phycoerythrin-conjugated mouse IgG as an isotype control (BD Bioscience, US). Data were acquired on FACSCanto™ II system (BD Bioscience, US) and were analyzed using the FlowJo software. The results were obtained from three independent experiments.

2.9. Blockade of IL-22R1 Signaling. To block IL-22R1 in HUVECs, the cells were incubated with human IL-22R1 antibody (AF2770; R&D systems, US) at a concentration of 8 μg/mL for 1 h prior to the addition of IL-22 (PeproTech, US) to the cell culture.

2.10. Statistical Analysis. Normally distributed variables were expressed as mean ± standard deviation (SD), nonnormally distributed variables were expressed as median (25th, 75th percentiles), and categorical variables were expressed as numbers (%). For the normally distributed variables, one-way analysis of variance or Dunnett’s t-test (for comparisons of two groups) was used to compare the cases. For nonnormally distributed variables, the Mann–Whitney U test was used to compare the cases, and the Kruskal-Wallis test was used to compare the subgroups. Spearman correlation coefficients were calculated for the associations between the cytokine levels and various laboratory markers. Associations between clinical parameters and the incidence of CAD and T2DM were first analyzed by simple logistic regression analysis and then by multivariate analysis. The odds ratios (ORs) for these variables reflect the change per one unit increase in the measure. P < 0.05 was considered to indicate statistical significance. All analyses were performed using SPSS 21.0 for Windows.

3. Results

3.1. Baseline Characteristics. The clinical characteristics of Batch 1 patients are outlined in Supplementary Material available online at http://dx.doi.org/10.1155/2016/8254797 (TEXT A and Table S1). Table 1 lists the characteristics of Batch 1 patients, five Th17-related cytokines were analyzed, and significantly higher levels of IL-22 were observed in the T2DM, CAD, and T2DM-CAD comorbidity patients than in the control individuals (Figure 1(b)). However, no differences in IL-17, IL-9, and MIP-3α...
levels were observed across the various groups (Figures 1(a), 1(c), and 1(e)). The IL-27 levels were higher in the T2DM-CAD comorbidity group than in the control group (Figure 1(d)).

Further expansions of sample size were carried out for a more comprehensive analysis. In Batch 2 analysis, serum IL-22 levels were significantly increased in the T2DM, CAD, and T2DM-CAD comorbidity groups compared with the control group (Figure 2(a)). There was no difference in the IL-22 level between the T2DM and CAD patients. T2DM-CAD patients showed significantly higher levels of IL-22 compared with the T2DM and CAD groups (Figure 2(a)).

Our results also revealed that the IL-22 level was significantly higher in patients with AMI and UA than in the control individuals (patients with AMI, n = 27 versus control, n = 110, P < 0.05; patients with UA, n = 53 versus control,
Table 2: Logistic regression analysis for the incidence of T2DM, CAD, and T2DM-CAD.

| Clinical parameters       | Simple regression |          | Multiple regression |          |
|---------------------------|-------------------|----------|---------------------|----------|
|                           | OR (95% CI)       | 𝑃        | OR (95% CI)         | 𝑃        |
| IL-22 (pg/mL)             | 1.042 (1.023, 1.062) | 0.000015 | 1.027 (1.004, 1.050) | 0.022    |
| Age (per/yr)              | 1.062 (1.039, 1.086) | 0.000000 | 1.082 (1.048, 1.111) | 0.000002 |
| Sex (male)                | 1.295 (0.840, 1.996) | 0.243    |                     |          |
| BMI (kg/m²)               | 0.991 (0.920, 1.067) | 0.811    |                     |          |
| Hypertension (yes)        | 1.750 (1.122, 2.728) | 0.014    | 0.916 (0.418, 2.009) | 0.827    |
| Stroke (yes)              | 2.978 (1.591, 5.754) | 0.001    | 0.940 (0.338, 2.614) | 0.905    |
| Smoking (yes)             | 0.937 (0.587, 1.494) | 0.783    |                     |          |
| Drinking (yes)            | 1.121 (0.613, 2.051) | 0.712    |                     |          |
| TC (per mmol/L)           | 1.062 (0.851, 1.326) | 0.595    |                     |          |
| TG (per mmol/L)           | 1.210 (0.946, 1.548) | 0.129    |                     |          |
| HDL (per mmol/L)          | 0.381 (0.183, 0.790) | 0.01     | 0.433 (0.152, 1.227) | 0.115    |
| LDL (per mmol/L)          | 1.043 (0.789, 1.379) | 0.766    |                     |          |
| FBS (per mmol/L)          | 1.690 (1.372, 2.082) | 0.000001 | 1.637 (1.316, 2.035) | 0.000009 |
| HbA1c (%)                 | 3.505 (2.243, 5.478) | 0.000000 | 1.388 (0.636, 3.031) | 0.411    |
| Urea (per mmol/L)         | 1.198 (1.058, 1.353) | 0.004    | 0.905 (0.747, 1.096) | 0.307    |
| Creatinine (per mmol/L)   | 1.018 (1.007, 1.028) | 0.001    | 1.007 (0.988, 1.026) | 0.411    |

![Figure 2](image_url)

Figure 2: Serum levels of interleukin-22 among the study groups. (a) Serum levels of IL-22 were determined in the control, T2DM, CAD, and T2DM-CAD groups by enzyme-linked immunosorbent assay (ELISA). (b) Serum levels of IL-22 were determined among the CAD subgroups and the control group by ELISA. Values are presented as medians (5th and 95th percentiles). *𝑃<0.05; **𝑃<0.01 versus control group.

Table S2 shows Spearman’s correlation between IL-22 and the risk factors for T2DM and CAD. IL-22 was negatively correlated with body mass index (𝑟 = −0.132; 𝑃 = 0.01) and total serum cholesterol levels (𝑟 = −0.12; 𝑃 = 0.01) and positively correlated with blood urea nitrogen (𝑟 = 0.105; 𝑃 = 0.04).

Table 2 shows the relationships between various clinical parameters (including IL-22 levels) and the incidence of T2DM, CAD, and T2DM-CAD. Simple logistic regression analysis revealed that age (OR 1.062, 95% CI 1.039 to 1.086; 𝑃 = 0.000000), hypertension (OR 1.750, 95% CI 1.122 to 2.728; 𝑃 = 0.014), stroke (OR 2.978, 95% CI 1.591 to 5.574; 𝑃 = 0.001), high-density lipoprotein (HDL; OR 0.381, 95% CI 0.183 to 0.790; 𝑃 = 0.01), fasting blood sugar (FBS; OR 1.690, 95% CI 1.372 to 2.082; 𝑃 = 0.000001), HbA1c (OR 3.505, 95% CI 2.243 to 5.478; 𝑃 = 0.000000), urea (OR 1.198, 95% CI 1.058 to 1.355; 𝑃 = 0.004), creatinine (OR 1.018, 95% CI 1.007 to 1.028; 𝑃 = 0.001), and IL-22 (OR 1.042, 95% CI 1.023 to 1.062; 𝑃 = 0.000015) were associated with the incidence of CAD and T2DM. The OR values were compared to the control group.

**𝑛 = 110, 𝑃 < 0.05; Figure 2(b).** There was no difference in the IL-22 level between patients with SA and healthy individuals (𝑃 > 0.05).
Mediators of Inflammation

Figure 3: Lysophosphatidylcholine (LPC) and glucose induce human umbilical vein endothelial cell (HUVEC) injury in a concentration-dependent manner. HUVECs were treated with different concentrations of LPC (5, 10, 20, and 40 μg/mL) and glucose (3, 15, 30, 60, and 90 mM) in Dulbecco’s Modified Eagle’s Medium (DMEM) for 24 h. Cell viability (relative to the control group) was analyzed using the CCK-8 assay. Data shown represent mean ± standard error of the mean (SEM) of three independent experiments. *P < 0.05; **P < 0.01 versus control group; ***P < 0.001.

Multiple regression analysis revealed that age (OR 1.082, 95% CI 1.048, 1.111; \( P = 0.000002 \)) and FBS (OR 1.637, 95% CI 1.316 to 2.035; \( P = 0.000009 \)) were significantly associated with the incidence of CAD and T2DM. Notably, IL-22 remained significantly and independently associated with the incidence of CAD and T2DM (OR 1.027, 95% CI 1.004 to 1.050; \( P = 0.022 \)). The OR values were compared to the control group.

3.3. LPC and Glucose Decrease the Cell Viability of HUVECs in a Concentration-Dependent Manner. First, to establish a suitable experimental model of HUVEC injury induced by LPC and high concentrations of glucose, we treated HUVECs with different concentrations of LPC (5, 10, 20, and 40 μg/mL) and glucose (5, 15, 30, 60, and 90 mM) in Dulbecco’s Modified Eagle’s Medium (DMEM) for 24 h and assessed the cell viability by using the CCK-8 assay. As shown in Figure 3(a), the relative optical density (OD) values of cells treated with 5, 10, 20, and 40 μg/mL LPC were 90.25% ± 5.75%, 58.63% ± 6.86%, 31.09% ± 9.07%, and 17.75% ± 4.88%, respectively. The cell viability of HUVECs treated with 10 μg/mL LPC decreased to 59% relative to that of control group. The relative OD values of cells treated with 5, 15, 30, 60, and 90 mM glucose were 93.11% ± 7.84%, 92.39% ± 4.35%, 90.22% ± 4.64%, 85.38% ± 4.17%, and 75.9% ± 10.19%, among which HUVECs treated with 30 mM glucose showed significantly decreased cell viability. These results suggest that 10 μg/mL LPC and 30 mM glucose are the appropriate concentrations to establish HUVEC injury model (Figure 3(b)). We also used 10 μg/mL LPC and 30 mM glucose as the combined stimuli.

3.4. IL-22 Protects HUVECs against LPC- and High Glucose-Induced Injury. To determine whether IL-22 has a direct effect on HUVEC cell viability, we treated DMEM cultivated HUVECs with different concentrations of IL-22; however, no change in cell viability was observed in any of the groups (Figure 4(c)). Next, we treated HUVECs with LPC (10 μg/mL) and glucose (30 mM) for 12 h, followed by treatment with different concentrations of IL-22 (20 ng/mL, 40 ng/mL, and 80 ng/mL) for 24 h. Cell viability was assessed by CCK-8 analysis. The cell viability of HUVECs decreased after treatment with 10 μg/mL LPC. In contrast, supplementation with IL-22 abolished the LPC-induced loss of cell viability (Figure 4(c)). The cell viability in the 40 ng/mL IL-22 + LPC group and the 80 ng/mL IL-22 + LPC group was significantly higher than that of the LPC-treated group. These results clearly demonstrated that IL-22 could protect HUVECs from LPC in a concentration-dependent manner. Similarly, in the presence of IL-22 (40 and 80 ng/mL) + 30 mM glucose, the cell viability was higher than that of the glucose-treatment group (Figure 5(c)).

Furthermore, to evaluate the effect of IL-22 on HUVEC apoptosis under different treatment conditions, the cells were incubated with DMEM, LPC, and a high concentration of glucose, accompanied with the addition of different concentrations of IL-22 (20, 40, and 80 ng/mL). No change in apoptotic rate was observed in the DMEM group treated with different concentrations of IL-22 (Figure 4(b)). However, IL-22 effectively attenuated LPC-induced apoptosis in HUVECs in a dose-dependent manner (Figure 4(b)). The percentage of cells undergoing apoptotic cell death decreased from 62.07% ± 3.9% in the LPC group to 49.2% ± 8.6%, 45.18 ± 8.5%, and 39.83% ± 10.1% after being exposed to 20, 40, and 80 ng/mL IL-22, respectively, for 24 h. Meanwhile, the apoptotic cell death decreased from 18.47% ± 2.8% in the high glucose group to 10.4% ± 1.5%, 8.4% ± 0.3%, and 8.33% ± 1.7% after being exposed to 20, 40, and 80 ng/mL IL-22, respectively, for 24 h (Figure 5(b)).
3.5. IL-22R1 Expression on HUVECs Was Enhanced upon Stimulation with LPC and High Concentrations of Glucose. The IL-22 receptor is a heterodimer composed of two subunits, IL-22R1 and IL-10R2. We attempted to detect IL-22R1 expression on HUVECs after treatment with high concentrations of glucose and LPC by flow cytometry. As shown in Figure 6(b), HUVECs exposed to LPC (10, 20, and 40 µg/mL) for 24 h exhibited a dose-dependent increase in IL-22R1 expression (13.13% ± 2.77%, 16.68% ± 6.15%, and 18.45% ± 4.19%, resp.) compared with the DMEM-treated group (4.87% ± 1.57%). HUVECs treated with high concentrations of glucose (30, 60, and 90 mM) also exhibited increased IL-22R1 expression (12.83% ± 2.97%, 14.83% ± 3.67%, and 14.45% ± 4.41%, resp.) compared with the DMEM-treated group (Figure 6(c)).

3.6. Blocking IL-22R1 Eliminated the Protective Role of IL-22 against LPC-, High Glucose-, and Combined Stimuli-Induced Injury on HUVECs. Because IL-22-targeting cells are restricted to nonimmune cells that express IL-22R1, we hypothesized that IL-22 exerts its protective role via IL-22R1. Therefore, we carried out IL-22R1 blocking experiments. IL-22 (40 ng/mL) increased the relative cell viability of LPC-, high glucose-, and LPC + high glucose-treated HUVECs from 64.88% ± 3.42%, 86.09% ± 2.85%, and 41.7% ± 4.66% to 78.14% ± 3.23%, 97.21% ± 4.3%, and 53.83% ± 5.21%, respectively. However, in the IL-22 + IL-22R1 antibody-treated group, the cell viability of HUVECs decreased to 70.68% ± 2.67%, 78.46% ± 8.57%, and 42.6% ± 5.73%, respectively (Figure 7(c)).

In addition, 40 ng/mL IL-22 decreased the apoptotic rate of LPC-, high glucose-, and LPC + high glucose-treated HUVECs from 56.37% ± 1.44%, 18.47% ± 2.84%, and 69.9% ± 2.85% to 44.5% ± 4.71%, 8.4% ± 0.26%, and 44.87% ± 3.32%, respectively. However, in the IL-22 + IL-22R1 antibody-treated group, the apoptotic rate of HUVECs increased to 49.27% ± 1.05%, 13.37% ± 2.21%, and 55.6% ± 1.73%, respectively (Figure 7(b)).

4. Discussion

Our results clearly demonstrated that patients with T2DM and CAD exhibit increased serum IL-22 levels. Elevated serum IL-22 is associated with the incidence of CAD and T2DM. However, further in vitro study established the protective role of IL-22 against endothelial dysfunction, an essential
process involved in the early development of atherosclerosis and vascular complications in T2DM [20, 21]. Potential stimuli present in T2DM and CAD condition, such as high glucose and LPC, lead to increased IL-22R1 expression on endothelial cells. To the best of our knowledge, this is the first report on the effect of these stimuli on IL-22R1 expression. Neutralizing IL-22R1 with IL-22R1 antibody diminished the protective role of IL-22. Together, our results suggest that IL-22 might exert different functions under different context. When used appropriately, IL-22 may have applications in the treatment of chronic inflammatory diseases such as T2DM and CAD.

In our study as well as in some previous studies, IL-22 was found to be increased in UA, AMI, and T2DM patients. However, no further mechanism-related research was reported before [22–24]. Our clinical study indicated the pathologic effects of IL-22. Our in vitro study, however, established the protective role of IL-22 in the endothelium. The beneficial effect of IL-22 reported here is consistent with some previous findings regarding its role in diabetes and atherosclerosis. Islet-endogenous and islet-exogenous IL-22 are able to suppress oxidative and endoplasmic reticulum stress caused by cytokines or glucolipotoxicity in mouse and human beta cells [25]. Additionally, IL-22 treatment improves keratinocyte prohealing functions in diabetes patients, suggesting a therapeutic potential for IL-22 in diabetic ulcer management [26]. In the case of atherosclerosis, IL-22−/− Apoe−/− mice exhibited reduced plaque size and decreased plaque collagen level, which are important in the maintenance of plaque stability. IL-22 might promote plaque growth and contribute to plaque stability during lesion formation [27].

In this study, we discovered an interesting “paradox.” Our clinical study revealed that elevated serum IL-22 is correlated with the incidence of T2DM and CAD independent of other clinical parameters. However, our cellular study showed that IL-22 might contribute to endothelium regeneration. The results are not mutually exclusive. As reported by Dudakov et al., upon acute tissue damage (such as in the case of our cellular model), IL-22 is presumably able to migrate to local lesions to promote endothelium survival and proliferation. However, long periods of chronic IL-22 overexpression (such as in our clinical context) could lead to the production of chemokines and other inflammatory signals and subsequent recruitment of pathologic effector cells to the inflamed tissues, leading to deterioration of disease condition [28]. In chronic hepatitis, IL-22-related pathology is dependent
Figure 6: LPC and high concentrations of glucose increased IL-22R1 expression in HUVECs. Representative flow cytometry histogram of IL-22R1 expression on HUVECs. Surface expression of IL-22R1 (open area) on HUVEC single-cell suspensions in comparison with the isotype control (filled area), as determined by flow cytometry. Green open area represents control group. Red open area represents LPC group. Yellow open area represents glucose group. The percentages of IL-22R1+ cells among the HUVECs were analyzed by using FlowJo. Data shown represent mean ± SEM of three independent experiments. *P < 0.05, **P < 0.01, and ***P < 0.0001 versus control group.

on the recruitment of Th17 cells [29]. The proinflammatory role of IL-22 has also been reported in the case of T2DM [12]. IL-22 amplifies IL-1β driven inflammation in human adipose tissue, thereby disrupting glucose homeostasis in obesity and T2DM. Whether IL-22 mediates a physiologic response or contributes to pathophysiologic inflammation probably depends on the context and/or cytokine milieu.

IL-22R is composed of two heterodimeric subunits, IL-22R1 and IL-10R2 [28]. IL-22 has a high affinity for IL-22R1 but no affinity for IL-10R2. Initial binding of IL-22 to the IL-22R1 subunit enables secondary binding of the IL-10R2 subunit, thereby enabling downstream signaling. The IL-22–IL-22R1 pathway has been reported to be able to contribute to migration and proliferation in hyperglycemic keratinocytes both in vitro and in vivo by inducing STAT3 phosphorylation [26]. Activation of the keratinocyte proliferative and prosurvival ERK1/2 pathways by IL-22 has also been observed in both hyperglycemic and diabetic patients [30]. Therefore, the IL-22–IL-22R1 signaling pathway in our context warrants further study.

Targeting the IL-22–IL-22R1 system might benefit chronic inflammatory diseases concerning the skin, chronic infections, pancreatitis, and so forth, although therapeutic modulation should be individualized [31]. In the case of psoriasis, inhibition of IL-22–IL-22R1 is recommended because the persistent regenerative role of IL-22 is pathogenic [32]. On the other hand, pancreatitis might benefit from supplementation of IL-22 because of its protective effects on pancreatic acinar cells and islet cells [33, 34]. Thus, the IL-22–IL-22R1 system can be protective or pathological depending
Figure 7: Treatment with IL-22R1 antibody ameliorated the protective role of IL-22 in LPC-, glucose-, or combination-treated HUVECs. Cells were treated with LPC (10 μg/mL), glucose (30 mM), or a combination of the two (10 μg/mL LPC + 30 mM glucose) for 12 h followed by incubation with 40 ng/mL IL-22 or 0.8 μg/mL IL-22R1 antibody + 40 ng/mL IL-22 for 24 h. IL-22R1 antibody (8 μg/mL) was added 1 h before treatment with 40 ng/mL IL-22. The apoptotic rate was quantified by flow cytometry. Data shown represent mean ± SEM of three independent experiments. *P < 0.01 versus control group; **P < 0.0001 versus control group. #P < 0.05 versus IL-22-treated group; ##P < 0.01 versus IL-22 treated group; ###P < 0.0001 versus IL-22 treated group.
on the context. Concerning that IL-22 might function like a double-edged sword during T2DM and CAD pathogenesis, the timing of IL-22–IL-22R1 application is crucial during the treatment of T2DM and CAD. Appropriate enhancement or reduction of IL-22–IL-22R1 depending on the context might have the potential to treat chronic inflammatory diseases such as T2DM and CAD in a comprehensive manner.

There are some limitations in our study. Because IL-22 is generated from a variety of T-cell subsets such as Th17, Th22, and γδ T cells, further analysis is required to track the origin of IL-22 and explore the function of the concerned immune cells. In addition, cross-sectional studies have intrinsic limitations. Whether the expression of IL-22 has a dynamic effect needs further investigation. In-depth analysis is underway to determine whether IL-22 is able to translate into a therapy for T2DM and CAD.

5. Conclusions

In conclusion, our results demonstrated that the serum IL-22 level is higher in T2DM, CAD, and T2DM-CAD comorbidity patients than in controls. Elevated serum IL-22 is associated with the incidence of T2DM and CAD. IL-22 is able to promote endothelial cells against LPC- and high glucose-induced injury. IL-22R1 might contribute to this beneficial effect of IL-22. Our results imply that IL-22 is a double-edged sword in CAD and T2DM. When used appropriately, IL-22 may have applications in the treatment of chronic inflammatory diseases such as T2DM and CAD.

Abbreviations

CAD: Coronary artery disease
LPC: Lysophosphatidylcholine
T2DM: Type 2 diabetes mellitus.

Competing Interests

The authors declare that they have no competing interests.

Acknowledgments

This work was supported by grants from the National Science Foundation of China (no. 81270428, no. 81300999, and no. 81470501). The authors gratefully acknowledge Dr. Lie Sun for the clinical sample collection.

References

[1] M.-A. Cornier, D. Dabelea, T. L. Hernandez et al., "The metabolic syndrome," Endocrine Reviews, vol. 29, no. 7, pp. 777–822, 2008.

[2] J. Frostegård, "Immune mechanisms in atherosclerosis, especially in diabetes type 2," Frontiers in Endocrinology, vol. 4, article 162, 2013.

[3] J. S. Rana, M. Nieuwdorp, J. W. Jukema, and J. J. P. Kastelein, "Cardiovascular metabolic syndrome—an interplay of, obesity, inflammation, diabetes and coronary heart disease," Diabetes, Obesity and Metabolism, vol. 9, no. 3, pp. 218–232, 2007.

[4] G. K. Hansson, A.-K. L. Robertson, and C. Söderberg-Nauclér, "Inflammation and atherosclerosis," Annual Review of Pathology, vol. 1, pp. 297–329, 2006.

[5] S. A. Huber, P. Sakkinen, C. David, M. K. Newell, and R. P. Tracy, "T helper-cell phenotype regulates atherosclerosis in mice under conditions of mild hypercholesterolemia," Circulation, vol. 103, no. 21, pp. 2610–2616, 2001.

[6] E. Fabbrini, M. Cella, S. A. McCartney et al., "Association between specific adipose tissue CD4+ T-cell populations and insulin resistance in obese individuals," Gastroenterology, vol. 145, no. 2, pp. 366–e3, 2013.

[7] S. Taleb, M. Romain, B. Ramkhelawon et al., "Loss of SOCS3 expression in T cells reveals a regulatory role for interleukin-17 in atherosclerosis," The Journal of Experimental Medicine, vol. 206, no. 10, pp. 2067–2077, 2009.

[8] Z. Su, H. Lu, H. Jiang et al., "IFN-γ-producing Th17 cells bias by HMGB1-T-bet/RUNX3 axis might contribute to progression of coronary artery atherosclerosis," Atherosclerosis, vol. 243, no. 2, pp. 421–428, 2015.

[9] B. Ip, N. A. Cilfone, A. C. Belkina et al., "Th17 cytokines differentiate obesity from obesity-associated type 2 diabetes and promote TNFα production," Obesity, vol. 24, no. 1, pp. 102–112, 2016.

[10] E. Smith, K.-M. R. Prasad, M. Butcher et al., "Blockade of interleukin-17A results in reduced atherosclerosis in apolipoprotein E-deficient mice," Circulation, vol. 121, no. 15, pp. 1746–1755, 2010.

[11] A. Gisterã, A.-K. L. Robertson, J. Andersson et al., "Transforming growth factor-β signaling in T cells promotes stabilization of atherosclerotic plaques through an interleukin-17-dependent pathway," Science Translational Medicine, vol. 5, no. 196, Article ID 196ra100, 2013.

[12] E. Dalmas, N. Venteclef, C. Caer et al., "T cell-derived IL-22 amplifies IL-1β-driven inflammation in human adipose tissue: relevance to obesity and type 2 diabetes," Diabetes, vol. 63, no. 6, pp. 1966–1977, 2014.

[13] X. Wang, N. Ota, P. Manzanillo et al., "Interleukin-22 alleviates metabolic disorders and restores mucosal immunity in diabetes," Nature, vol. 514, no. 7521, pp. 237–241, 2014.

[14] S. Ghannam, C. Dejou, N. Pedretti et al., "CCL20 and β-defensin-2 induce arrest of human Th17 cells on inflamed endothelium in vitro under flow conditions," The Journal of Immunology, vol. 186, no. 3, pp. 1411–1420, 2011.

[15] G. L. Stephens, B. Swerdlow, E. Benjamin et al., "IL-9 is a Th17-derived cytokine that limits pathogenic activity in organ-specific autoimmune disease," European Journal of Immunology, vol. 41, no. 4, pp. 952–962, 2011.

[16] A. Peters, K. D. Fowler, F. Chalmin, D. Merkler, V. K. Kuchroo, and C. Pot, "IL-27 induces Th17 differentiation in the absence of STAT1 signaling," Journal of Immunology, vol. 195, no. 9, pp. 4144–4153, 2015.

[17] C. Duffaut, A. Zakaroff-Girard, V. Bourlier et al., "Interplay between human adipocytes and T lymphocytes in obesity: CCL20 as an adipochemokine and T lymphocytes as lipogenic modulators," Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 29, no. 10, pp. 1608–1614, 2009.

[18] I. Gregersen, M. Skjelland, S. Holm et al., "Increased systemic and local interleukin 9 levels in patients with carotid and coronary atherosclerosis," PLoS ONE, vol. 8, no. 8, Article ID e72769, 2013.
[19] H. Fu, Y.-Y. Tang, X.-P. Ouyang et al., "Interleukin-27 inhibits foam cell formation by promoting macrophage ABCA1 expression through JAK2/STAT3 pathway," *Biochemical and Biophysical Research Communications*, vol. 452, no. 4, pp. 881–887, 2014.

[20] F. Paneni, J. A. Beckman, M. A. Creager, and F. Cosentino, "Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part I," *European Heart Journal*, vol. 34, no. 31, pp. 2436–2446, 2013.

[21] P. O. Bonetti, L. O. Lerman, and A. Lerman, "Endothelial dysfunction: a marker of atherosclerotic risk," *Arteriosclerosis, Thrombosis, and Vascular Biology*, vol. 23, no. 2, pp. 168–175, 2003.

[22] R. Zhao, D. Tang, S. Yi et al., "Elevated peripheral frequencies of Th22 cells: a novel potent participant in obesity and type 2 diabetes," *PLoS ONE*, vol. 9, no. 1, Article ID e85770, 2014.

[23] L. Zhang, T. Wang, X.-Q. Wang et al., "Elevated frequencies of circulating Th22 cell in addition to Th17 cell and Th17/Th1 cell in patients with acute coronary syndrome," *PLoS ONE*, vol. 8, no. 12, Article ID e71466, 2013.

[24] Y.-Z. Lin, B.-W. Wu, Z.-D. Lu et al., "Circulating Th22 and Th9 levels in patients with acute coronary syndrome," *Mediators of Inflammation*, vol. 2013, Article ID 635672, 10 pages, 2013.

[25] S. Z. Hasnain, D. J. Borg, B. E. Harcourt et al., "Glycemic control in diabetes is restored by therapeutic manipulation of cytokines that regulate beta cell stress," *Nature Medicine*, vol. 20, no. 12, pp. 1417–1426, 2014.

[26] S. Avitabile, T. Odorisio, S. Madonna et al., "Interleukin-22 promotes wound repair in diabetes by improving keratinocyte pro-healing functions," *Journal of Investigative Dermatology*, vol. 135, no. 11, pp. 2862–2870, 2015.

[27] S. Rattik, K. Hultman, U. Rauch et al., "IL-22 affects smooth muscle cell phenotype and plaque formation in apolipoprotein E knockout mice," *Atherosclerosis*, vol. 242, no. 2, pp. 506–514, 2015.

[28] J. A. Dudakov, A. M. Hanash, and M. R. M. van den Brink, "Interleukin-22: immunobiology and pathology," *Annual Review of Immunology*, vol. 33, pp. 747–785, 2015.

[29] J. Zhao, Z. Zhang, Y. Luan et al., "Pathological functions of interleukin-22 in chronic liver inflammation and fibrosis with hepatitis B virus infection by promoting T helper 17 cell recruitment," *Hepatology*, vol. 59, no. 4, pp. 1331–1342, 2014.

[30] S. Pastore, F. Mascia, F. Mariotti, C. Dattilo, V. Mariani, and G. Girolomoni, "ERK1/2 regulates epidermal chemokine expression and skin inflammation," *The Journal of Immunology*, vol. 174, no. 8, pp. 5047–5056, 2005.

[31] R. Sabat, W. Ouyang, and K. Wolk, "Therapeutic opportunities of the IL-22–IL-22R1 system," *Nature Reviews Drug Discovery*, vol. 13, no. 1, pp. 21–38, 2014.

[32] K. Wolk, S. Kunz, E. Witte, M. Friedrich, K. Asadullah, and R. Sabat, "IL-22 increases the innate immunity of tissues," *Immunity*, vol. 21, no. 2, pp. 241–254, 2004.

[33] J. Xue, D. T. C. Nguyen, and A. Habtezion, "Aryl hydrocarbon receptor regulates pancreatic IL-22 production and protects mice from acute pancreatitis," *Gastroenterology*, vol. 143, no. 6, pp. 1670–1680, 2012.

[34] D. Feng, O. Park, S. Radaeva et al., "Interleukin-22 ameliorates cerulein-induced pancreatitis in mice by inhibiting the autophagic pathway," *International Journal of Biological Sciences*, vol. 8, no. 2, pp. 249–257, 2012.